<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859584</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00385-36</org_study_id>
    <nct_id>NCT02859584</nct_id>
  </id_info>
  <brief_title>ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS</brief_title>
  <acronym>CORT-HEPAT</acronym>
  <official_title>ASSESSMENT OF ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS USING CONCENTRATION OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A high frequency of adrenal dysfunction (AD) has been reported in severe acute hepatitis&#xD;
      (SAH) using the dosage of serum total cortisol (STC). Because 90% of circulating serum&#xD;
      cortisol is bound to proteins that are altered in SAH, we aimed to investigate the effect of&#xD;
      decreased cortisol-binding proteins on STC, serum free cortisol (SFC) and salivary cortisol&#xD;
      (SalivCort) in SAH.&#xD;
&#xD;
      Baseline (T0) and cosyntropin-stimulated (T60) STC, SFC and SalivCort concentrations were&#xD;
      measured&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We prospectively and consecutively enrolled 75 patients suffering from a SAH (n=44) or a NSAH&#xD;
      (n=31). Inclusion criteria were patients aged between 18 and 75 years with an acute hepatitis&#xD;
      defined by an abrupt rise in serum aminotransaminase levels during the 15 previous days (AST&#xD;
      or ALT greater than 500 IU/L or greater than 10 times the upper normal value); the acute&#xD;
      hepatitis was considered as severe if the prothrombin index was lower than 50% and as&#xD;
      non-severe if it was greater than 50%. We excluded patients with the following conditions: a&#xD;
      history of hypothalamic-pituitary or adrenal disease, corticosteroids treatment within the&#xD;
      previous 6 months, ketoconazole intake, oral candida infection, any visible bleeding in the&#xD;
      oral cavity, liver transplanted patients, acute alcoholic hepatitis and night workers.&#xD;
      Twenty-nine healthy controls (HC) were thereafter enrolled and similarly distributed with the&#xD;
      SAH group on age, sex and estrogen pill intake, estrogen therapy being the most common cause&#xD;
      for changes in CBG levels. HC were without any known illnesses and were not receiving any&#xD;
      medications. To evaluate the range of the SFC concentrations, eight patients with a known AD&#xD;
      caused by impairment of hypothalamic-pituitary-adrenal axis (n=5) and adrenal gland (n=3) and&#xD;
      followed at the Endocrinology Department of Besancon were also studied.&#xD;
&#xD;
      STC, SFC and salivary cortisol concentrations were measured blindly before (T0 between 8am&#xD;
      and 9am) and 60 minutes after (T60) an intravenous injection of 250 µg tetracosactrin&#xD;
      (synacthenÒ, Sigma-Tau laboratory, France). Serum CBG, albumin and ACTH were also measured&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of the serum total cortisol (STC) in SAH.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of the serum free cortisol (SFC) in SAH.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of the salivary cortisol (SalivCort) in SAH.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Acute Hepatitis</condition>
  <arm_group>
    <arm_group_label>no serious acute hepatitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Serious acute hepatitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Surrenal insufficiency</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Serious acute hepatitis</arm_group_label>
    <arm_group_label>Surrenal insufficiency</arm_group_label>
    <arm_group_label>no serious acute hepatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion of 101 test subjects and for statistical analysis:&#xD;
&#xD;
               -  29 patients with non-acute severe hepatitis (TP&gt; 50% and AST or ALT&gt; 500 IU / L&#xD;
                  or&gt; 10 xN for less than 15 days).&#xD;
&#xD;
               -  43 patients with severe acute hepatitis (TP &lt;50%). Patients with suspected IS&#xD;
                  with the assay of the CTS will retested at Synacthène 4 to 6 months later (10&#xD;
                  desired subjects).&#xD;
&#xD;
               -  29 healthy volunteers (control group included in the analysis).&#xD;
&#xD;
          -  Inclusion of 10 patients with established IS (control group to estimate the low values&#xD;
             of cortisol).&#xD;
&#xD;
          -  Patient who signed the consent of study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women during pregnancy or breastfeeding&#xD;
&#xD;
          -  Minor and over 75 years&#xD;
&#xD;
          -  Major protected within the meaning of Huriet&#xD;
&#xD;
          -  Subject healthy volunteers in a sport competition&#xD;
&#xD;
          -  Patients transplanted, HIV infection (also refusing HIV status) or patients on&#xD;
             immunosuppressive therapies (including corticosteroids)&#xD;
&#xD;
          -  ketoconazole Shot, rifampicin, mifepristone, megestrol or etomidate&#xD;
&#xD;
          -  Treatment with corticosteroids irrespective of the route of administration&#xD;
&#xD;
          -  severe acute alcoholic hepatitis&#xD;
&#xD;
          -  oral fungal infection&#xD;
&#xD;
          -  upper gastrointestinal bleeding or oral bleeding (contamination salivettes)&#xD;
&#xD;
          -  unbalanced Diabetes&#xD;
&#xD;
          -  unbalanced Hypertension&#xD;
&#xD;
          -  Chronic heart failure (stage III or IV of the classification of the New York Heart&#xD;
             Association [NYHA])&#xD;
&#xD;
          -  Inability to receive clear information in patients with severe encephalopathy and do&#xD;
             not have someone you trust&#xD;
&#xD;
          -  Refusal of the participation agreement by signing the form of information and consent&#xD;
             as defined in the protocol.&#xD;
&#xD;
          -  exclusion period from another biomedical study&#xD;
&#xD;
          -  Septic shock&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21281437</url>
    <description>article</description>
  </link>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute hepatitis</keyword>
  <keyword>acute liver failure</keyword>
  <keyword>adrenal dysfunction</keyword>
  <keyword>salivary cortisol</keyword>
  <keyword>serum free cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

